Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Platelet phenolsulphotransferase activity in Parkinson's disease.

Literature DB >> 6578300

Platelet phenolsulphotransferase activity in Parkinson's disease.

V Glover, A J Lees, C Ward, G M Stern, M Sandler.

Abstract

Mean platelet phenolsulphotransferase activity was significantly increased in L-dopa-treated parkinsonian patients compared with controls. The degree of rise was associated with dose of and duration of treatment with L-dopa and may thus represent an adaptive increase to circulating dopamine. Alternatively, the increase may reflect changes supervening with duration of illness.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1983 PMID： 6578300 DOI： 10.1007/bf01250051

Source DB: PubMed Journal: J Neural Transm Impact factor: 3.575

16 in total

1. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.

Authors: R L Bronaugh; R J MacMurtry; M M Hoehn; C O Rutledge
Journal: Biochem Pharmacol Date: 1975-07-15 Impact factor: 5.858

2. Sulphate conjugation and L-dopa treatment of Parkinsonian patients.

Authors: C O Rutledge; M M Hoehn
Journal: Nature Date: 1973-08-17 Impact factor: 49.962

3. Enhanced tyramine conjugation in Parkinson's disease.

Authors: S M Carter; M B Youdim; M Sandler; K R Hunter; G M Stern
Journal: Clin Chim Acta Date: 1974-03-26 Impact factor: 3.786

4. Effect of pretreatment with oestradiol, progesterone and DOPA on monoamine oxidase activity in the rat.

Authors: G G Collins; J Pryse-Davies; M Sandler; J Southgate
Journal: Nature Date: 1970-05-16 Impact factor: 49.962

5. Sulfation of dopamine and other biogenic amines by human brain phenol sulfotransferase.

Authors: K J Renskers; K D Feor; J A Roth
Journal: J Neurochem Date: 1980-06 Impact factor: 5.372

6. Free and conjugated plasma and urinary dopamine in human hypertension.

Authors: O Kuchel; N T Buu; T Unger; M Lis; J Genest
Journal: J Clin Endocrinol Metab Date: 1979-03 Impact factor: 5.958

7. Parkinsonism: onset, progression and mortality.

Authors: M M Hoehn; M D Yahr
Journal: Neurology Date: 1967-05 Impact factor: 9.910

8. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.

Authors: E A Zeller; B Boshes; J Arbit; M Bieber; E R Blonsky; M Dolkart; S V Huprikar
Journal: J Neural Transm Date: 1976 Impact factor: 3.575

9. Sulphate conjugation of biologically active monoamines and their metabolites by human platelet phenolsulphotransferase.

Authors: G Rein; V Glover; M Sandler
Journal: Clin Chim Acta Date: 1981-04-09 Impact factor: 3.786

10. Human platelet phenolsulphotransferase: separate control of the two forms and activity range in depressive illness.

Authors: S M Carter; V Glover; M Sandler; P K Gillman; P K Bridges
Journal: Clin Chim Acta Date: 1981-12-24 Impact factor: 3.786

3 in total

1. Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients.

Authors: P Bongioanni; M Donato; M Castagna; F Gemignani
Journal: J Neural Transm (Vienna) Date: 1996 Impact factor: 3.575

2. Minoxidil sulphation in human liver and platelets. A study of interindividual variability.

Authors: G M Pacifici; R Bigotti; G Marchi; L Giuliani
Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953

3. Interindividual variability of phenol- and catechol-sulphotransferases in platelets from adults and newborns.

Authors: G M Pacifici; G Marchi
Journal: Br J Clin Pharmacol Date: 1993-12 Impact factor: 4.335

3 in total